Analysis of investment opportunities in plant extract market segments

Investment opportunities in stevioside Market CIC consultant pointed out in the report on investment analysis and Prospect Forecast of China's plant extract Market in 2016-2020 that after the US passed gras certification in 2009, the market demand of Stevia (glycoside) industry increased sharply, and domestic suppliers also seized the opportunity to rush in time, leading to a serious oversupply of Stevia glycoside in the market in 2012, and the market was once depressed In 2012, the export value of stevioside was more than 5 million US dollars, ranking 27th among all the plant extracts exported in China In 2013, the top 30 plant extracts exported from China did not show the shadow of Stevia As of 2014, stevioside ranked 32nd in the export varieties, but the export volume has halved compared with 2012 In 2014, the planting area of Stevia leaf increased by 50% compared with the same period in 2013, and the market price also increased by about 40% compared with the same period in 2013 Of course, speculation is not ruled out The market price of steviol glycoside has also risen It has increased since April 2014 By the end of 2014, the market price of steviol glycoside had risen to about 30% The main suppliers of stevioside in China are concentrated in Shandong, Jiangxi and other regions In 2015, the supply pattern of stevioside in domestic market changed little, and the output of major suppliers was basically stable Mulberry leaf extract market investment opportunities mulberry leaf extract in the past three years continued to appear in the top 25 plant extract exports The export volume of mulberry leaf extract in 2012-2013 is the same, and the export volume in 2014 is about 20% lower than that in 2013 In 2014, the market price of mulberry leaf increased by 30%, and the market price of mulberry leaf extract increased by about 15% At present, the countries with the most demand for mulberry leaf extract are mainly in Asia such as Japan, South Korea and China, and in Western Europe such as Germany, France and the United States In 2014, Japan and the United States saw a significant increase in market demand Japanese and Korean markets are mainly used in cosmetics -- whitening effect of mulberry leaf extract; Western European and American markets are mainly used in health products and drugs -- hypoglycemic and blood pressure reducing effects With more and more people and younger age, there will be more and more demand for mulberry leaf extract in domestic market and international market in the future Investment opportunities of ginseng extract market the market export volume of ginseng extract in 2012-2014 has tripled, and it is also one of the varieties with very strong growth of all plant extracts The market demand of ginseng extract increased, and the market price of ginseng extract basically changed little Only in 2014, due to market speculation and other reasons, the market price of ginseng had a short period of high price fluctuation in the new production period After several large-scale purchasing enterprises in the industry jointly suppressed, ginseng entered a rational market In the future, the market price of ginseng extract will continue to run stably, excluding human speculation Paclitaxel market investment opportunities paclitaxel is the first choice of anti-tumor drugs in hospitals all over the world, and its importance is self-evident In recent years, the incidence rate of cancer in the world has nearly doubled compared with that of 10 years ago Before there is no new plant anticancer drug to replace its position, the sales of taxol will only rise, and it will not drop With the rapid expansion of clinical application, paclitaxel has been used in the treatment of advanced breast cancer, prostate cancer, Kaposi's sarcoma, head and neck cancer, skin cancer and other common malignant tumors The global total sales of taxol is increasing at the rate of 20% / year, which shows that the market demand for taxol is increasing However, due to the lack of production, the contradiction of supply shortage is increasingly significant Paclitaxel has been in short supply for a long time, and it also faces market monopoly At present, there are only two kinds of paclitaxel APIs in the international market, one is from all kinds of Taxus bark; the other is to extract "10-berrychianthine" from European ornamental Taxus branches, and then through semi synthesis, namely docetaxel (docetaxel) Its structure is very similar to that of natural extraction of paclitaxel Paclitaxel has always been the exclusive product of Squibb in the United States, bringing more than one billion dollars of revenue to Squibb every year Although the FDA of the United States agreed at the end of 2000 that other manufacturers can also produce paclitaxel preparations In the future, more pharmaceutical companies will join in the production of paclitaxel preparations, but in the short term, the monopoly position will not change significantly In the future, the demand for paclitaxel API will rise and fall, and the sales of paclitaxel will continue to rise and fall Countries around the world will also increase efforts to overcome the bottleneck of insufficient capacity With the continuous improvement of technology, it is believed that the production of paclitaxel by cell culture will become one of the key measures to solve the bottleneck of supply of paclitaxel API Astaxanthin market investment opportunity astaxanthin is a kind of super antioxidant, occupying nearly 90% market share of antioxidant products, especially in Europe Up to now, there are 23 patents for prawn cyanin Because of such strong market demand, the international giant suppliers have expanded their production, and the main suppliers of astaxanthin in China are also actively expanding their production With the maturity of production technology and the increase of market competitiveness, the market of astaxanthin is in reverse development - increasing market demand and decreasing market price The market price of astaxanthin decreased by 10% in 2014 due to the market competitiveness and mature technology The future market trend is expected.